Literature DB >> 18690806

Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758).

J Humberto Tapia-Perez1, Martin Sanchez-Aguilar, Jaime Gerardo Torres-Corzo, Antonio Gordillo-Moscoso, Patricia Martinez-Perez, Peter Madeville, Esperanza de la Cruz-Mendoza, Juan Chalita-Williams.   

Abstract

Amnesia is a common sequela following traumatic brain injury (TBI), for which there is no current treatment. Pleiotropic effects of statins have demonstrated faster recovery of spatial memory after TBI in animals. We conducted a double-blind randomized clinical trial add-on of patients with TBI (16-50 years of age), with Glasgow Coma Scale (GCS) scores of 9-13, and intracranial lesions as demonstrated by computed tomography (CT) scan. We excluded those patients with recent head injury or severe disability; administration of known drugs as modifiers of statin metabolism; multisystemic trauma; prior use of mannitol, barbiturate, corticosteroids, indomethacin or calcium antagonists; surgical or isolated lesion in brainstem; allergy to statins; previous hepatopathy or myopathy; previous management in another clinic; or pregnancy. Each patient received the same treatment and was randomly allocated to receive either rosuvastatin (RVS) or placebo over a period of 10 days. The primary outcome measures assessed were amnesia and disorientation times using Galveston Orientation Amnesia Test. Additionally, we evaluated plasma levels of interleukin (IL) 1beta, tumor necrosis factor (TNF) alpha, and IL-6, as well as disability at 3 months. We analyzed eight patients with RVS and 13 controls with similar basal characteristics. Using Cox regression analysis, administration of RVS showed a reduction of amnesia time with a hazard ratio of 53.76 (95% confidence interval [CI], 1.58-1824.64). This was adjusted for early intubation, basal leukocytes, basal Marshall and Fisher score, change of IL-1beta levels, and lesion side. IL-6 values at day 3 were increased in the RVS group (p = 0.04). No difference was detected in disability at 3 months. While statins may reduce amnesia time after TBI, possibly by immunomodulation, further trials are needed in order to confirm this positive association.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690806     DOI: 10.1089/neu.2008.0554

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  32 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Achieving high research reporting quality through the use of computational ontologies.

Authors:  Amrapali Zaveri; Luciana Cofiel; Jatin Shah; Shreyasee Pradhan; Edwin Chan; Olivier Dameron; Ricardo Pietrobon; Beng Ti Ang
Journal:  Neuroinformatics       Date:  2010-12

Review 3.  Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.

Authors:  David J Loane; Alan I Faden
Journal:  Trends Pharmacol Sci       Date:  2010-10-29       Impact factor: 14.819

Review 4.  Medical Management of the Severe Traumatic Brain Injury Patient.

Authors:  Jonathan Marehbian; Susanne Muehlschlegel; Brian L Edlow; Holly E Hinson; David Y Hwang
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

Review 5.  The far-reaching scope of neuroinflammation after traumatic brain injury.

Authors:  Dennis W Simon; Mandy J McGeachy; Hülya Bayır; Robert S B Clark; David J Loane; Patrick M Kochanek
Journal:  Nat Rev Neurol       Date:  2017-02-10       Impact factor: 42.937

6.  Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier.

Authors:  Major Gooyit; Mark A Suckow; Valerie A Schroeder; William R Wolter; Shahriar Mobashery; Mayland Chang
Journal:  ACS Chem Neurosci       Date:  2012-07-30       Impact factor: 4.418

7.  Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells.

Authors:  Tammy A Butterick; Urule Igbavboa; Gunter P Eckert; Grace Y Sun; Gary A Weisman; Walter E Müller; W Gibson Wood
Journal:  Mol Neurobiol       Date:  2010-04-06       Impact factor: 5.590

Review 8.  The role of statins in neurosurgery.

Authors:  Jorge Humberto Tapia-Pérez; Martin Sanchez-Aguilar; Thomas Schneider
Journal:  Neurosurg Rev       Date:  2010-04-29       Impact factor: 3.042

Review 9.  Cell Death and Recovery in Traumatic Brain Injury.

Authors:  Yosuke Akamatsu; Khalid A Hanafy
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

Review 10.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.